Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000418497 | SCV000530409 | uncertain significance | not provided | 2023-03-21 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 34662886) |
Fulgent Genetics, |
RCV002480316 | SCV002783192 | uncertain significance | Adult hypophosphatasia; Childhood hypophosphatasia; Infantile hypophosphatasia | 2021-12-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000418497 | SCV003515431 | uncertain significance | not provided | 2022-10-09 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 261 of the ALPL protein (p.Pro261Leu). This variant is present in population databases (rs765149569, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with ALPL-related conditions. ClinVar contains an entry for this variant (Variation ID: 388169). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ALPL protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001828429 | SCV002094073 | uncertain significance | Hypophosphatasia | 2019-10-28 | no assertion criteria provided | clinical testing |